The function of this folate binder is unknown. However, that it reacts with dihydrofolate suggests some relationship (physiologic or pathologic) to DNA synthesis since this folate cofactor is essential for the de novo synthesis of thymidylate from deoxyuridylate. In addition, these findings also suggest that the binding of methotrexate may, like folate, inhibit its reaction with folate reductase, and thus be a mechanism by which leukemic cells become resistant to this drug.
INTRODUCTION
The cellular uptake of folic acid has been studied by several investigators (1) (2) (3) and there is suggestive but no direct evidence for an intracellular binding site other than folate reductase (Enzyme Commission 1.5.1.3), the enzyme which catalyzes the reduction of folate and dihydrofolate to tetrahydrofolate (4) . In blood, as well, there is no definite evidence for a specific folate binder. When folic acid is added to serum, the per cent bound remains fairly constant over a wide concentration range (5), the binding is reversible (6) , and the bound vitamin can easily be extracted with charcoal (7) .
A previous communication from this laboratory (8) presented evidence that the lysate of cells from two patients with chronic myelogenous leukemia, bound tritiated folic acid. This binding factor has now been found in the cell lysates from two additional patients with this disease. Serum available for testing from three of these patients also contained a folate binder. The properties of this binding factor have been studied in detail and the findings form the basis of this report.
METHODS
Tritiated folic acid (FA-3H or tracer FA) was purchased from Amersham/Searle Corp., Arlington Heights, Ill. The purity of this compound, established by coprecipitation with unlabeled folic acid (FA), varied from 70 to 90% and appropriate corrections were made for this nonfolate radioactivity (9 The radioactivity of aliquots of the column fractions and the charcoal and Dowex supernatants was assayed in 15 ml of a scintillation solution containing 5 g of 2,5-diphenyloxazole and 50 ml of BBS-3 solubilizer (Beckman Instruments, Inc., Fullerton, Calif.) per liter toluene use of a liquid scintillation counter (Nuclear-Chicago, Des Plaines, Ill.). Sufficient counts were accumulated for a counting error of 4%o or less.
The effect of hydrogen ion concentration on the binding of FA--H was studied using mixtures of 0.05 M citric acid and 0.05 M sodium citrate as the diluent for the reactions of pH 7.6 or below. 0.02 M Tris was used with either 0.1 N NaOH or 0.1 N HCl for pH values greater than 7.6. The effect of temperature was determined by heating binding lysate and lysate-bound FA-8H at 560C. The specificity of the binding factor was studied by determining the competitive effect of unlabeled folic acid and other pteridine analogues on the binding of FA-AH. The rate of binding of FA-3H was studied by removing an aliquot of a reaction mixture at timed intervals and rapidly adding it to 0.5 ml of the coated charcoal suspension. Dissociation was studied by adding a swamping excess of unlabeled folic acid (0.15 mg) to FA-3H previously incubated with binding lysate, and at timed intervals determining the bound radioactivity by adding an aliquot of the reaction mixture to 0.5 ml of the charcoal suspension.
RESULTS
The filtration patterns of FA-'H through G-75
Sephadex with buffer alone and after incubation with the lysates of various leukemic cells, normal bone marrow, and normal leukocytes are shown in the radiochromatograms in Fig. 1 . After incubation with CML-2, CML-3, or CML-4 cell lysates the major fraction of radioactivity filtered with the early effluent indicating that tracer folate was bound to a factor with a mol wt of at least 50,000. In contrast, after incubation with the lysates of other cells, or when filtered alone, all of the tracer appeared with the inner volume indicating that the folate was either free or bound to a factor with a mol wt of less than 50,000. The radiochomatograms in Fig. 2 show that FA-3H incubated with CML-2 lysate filtered with the early fractions through G-100 as well as G-75 but appeared with the inner volume through G-200 Sephadex. When CML-2 lysate was subjected to centrifugation at 105,000 g for 60 min and the supernate incubated with FA-8H, the radioactivity again filtered with the excluded volume of G-75 Sephadex (Fig. 2 b) . Thus, this FA-binding factor appears in the soluble fraction of the cell cytoplasm and has a mol wt between 100,000 and 200,000.
The filtration of FA-3H through G-75 Sephadex after incubation with serum from CML-2 and CML-3 patients is shown in Fig. 3 . For these experiments the reaction mixture was treated with 200 mg of dry albumin coated charcoal to remove free FA-3H before filtration. Most of the radioactivity not removed by charcoal appeared in the early fractions indicating that the serum from these patients also bound folic acid. The small fraction of radioactivity appearing with the inner volume was, for the most part, an impurity in the FA-'H preparation which also could not be adsorbed from buffer solution with charcoal. Some of this nonadsorbable radioactivity may have also been bound to low molecular weight serum proteins, but it represented only a small per cent of the total radioactivity added. When other leukemic serums, obtained from patients without the binding factor in their cell lysates, and normal serums were incubated with FA-8H and similarly treated with charcoal, the small fraction of unadsorbed radioactivity filtered with the inner volume of the column and no FA-'H appeared with the early effluent. ied by adding a swamping quantity of stable the reaction mixture after it had incubated then determining the decrease in bound I addition of the coated charcoal suspension.
the CML-2 lysate was serially diluted before the active leukemic lysate.
The FA binder in CML-2 lysate could be separated from endogenous folate reductase by filtration through a G-75 Sephadex column and assaying the effluent fractions for folate reductase and for "inhibition" of enzyme activity in a leukemic lysate which did not bind FA. As shown in Fig. 5 , endogenous folate reductase activity appeared with the fractions of the inner volume. The early effluent fractions, however, inhibited the reductase activity of the test leukemic lysate. These inhibitory fractions corresponded to the early appearance of "bound" FA-3H shown in Fig. 1 I ( ), number of samples tested. 11 A few values less than 0.5% were considered as zero. Extract alone was treated at 560C for 30 min and the binding of FA-3H determined at 250C using coated charcoal. § The mixture of lysate and FA-3H was incubated at 25°C for 30 min and then at 56°C for 30 min and the bound FA-3H was then determined using the coated charcoal. Fig. 6 . The forward velocity was extremely rapid with a rate of approximately 1.0%/sec. There was virtually no dissociation of the bound FA-5H for the first 30 min of observation either at room temperature or 37°C, and even after 24 hr only 14% of the FA-5H dissociated.
The effect of therapy on the FA binder in the cells and serum of patient CML-3 was studied after she was treated with busulfan. The radiochromatograms in Fig. 7 demonstrate that the binder was still evident in the cell lysate after treatment (peripheral leukocyte count of (17) might be explained by such a binding factor which could result in intracellular folate accumulation even in the face of an energy-dependent efflux mechanism recently described by Lichtenstein, Oliverio, and Goldman (18) . The evidence for binding of FH2 adds some logic to the properties of this factor which initially appeared to bind a form of folate less physiologic than the completely reduced folate cofactors which it did not bind. It is perhaps more reasonable to speculate that the function (physiologic or pathologic) of this factor is to bind FH2, a key folate analogue in the synthesis of thymidylate from deoxyuridylate. As a pathologic factor, or even as a normal factor in excess, it could interfere with such synthesis and perhaps be responsible for a longer cell generation time (19) (23) . The finding of significantly higher Km values for the reduction of folic acid or FH2 by whole lysates containing this binding factor indicates that caution must be exercised when interpreting studies which demonstrate altered enzyme properties. Clearly any factor which effectively prevents a substrate from reacting with an enzyme will result in a higher concentration of the substrate necessary to achieve half maximal velocity of the enzyme. Although this phenomenon has not been identified in protozoan cells (24) recently reported to contain folate reductase with an altered Km, it has not been excluded.
The folate-binding pattern of this factor is similar to the antifolate antibody obtained by immunizing rabbits with folic acid coupled to methylated bovine albumin (25) . Since an immunoassay with this antibody can reveal immunoreactive FA in serum and whole blood extracts (26) , this macromolecule may have practical value as a binder for a competitive inhibition radioassay for folic acid in blood. This application is presently under investigation.
A more speculative consideration at this time is the potential value of such a binding factor in the treatment of neoplastic processes. Since the binding of FA prevents its enzymatic reduction, it is likely that reduction of FH2 would be similarly prevented by this factor no matter how high the concentration of reducing enzyme. As MTX interrupts the cycle of thymidylate synthesis by inhibiting folate reductase and preventing recycling of FH2 to FH4, so this binder could similarly inhibit this process by binding this cofactor. Although the size of this binder would generally preclude its entry into most cells, there is evidence that some macromolecules can penetrate tumor cells (27) . Nevertheless, this potential application will require more definitive knowledge as to the chemical nature, structure, and reacting site of this FA-binding factor.
